

September 7, 2022

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir / Madam,

Sub: Participation in Investors' meet

Further to our letter dated September 6, 2022 informing about the participation in the Kotak Institutional Equity Healthcare Forum 2022 on September 8, 2022, we inform you that the presentation updated in the following weblink of the Company will be used during the interaction with the investors.

https://www.aurobindo.com/wp-content/uploads/2022/09/Aurobindo-Pharma_Investor-Presentation_INR_Sep-22.pdf

No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions.

This intimation is submitted pursuant to Regulation 30(6) of the Listing Regulations.

Please take the above information on record.

Thanking you,

Yours faithfully,

For AUROBINDO PHARMA LIMITED



B. Adi Reddy
Company Secretary